The Oral Transition in Rare Disease Crisis Management: Deucrictibant, Bradykinin B2 Receptors, and the Next Phase of Acute HAE Care
Dr. Dereck Mush, MD, MBAThe Signal franchises
MembersDeep Dives
One long form investigation at a time. Original reporting, primary documents, and the numbers behind the headline, written for people who decide where health technology money and policy go.
Dr. Dereck Mush, MD, MBA
Beyond HER2 and TROP2: How AbbVie's c-Met Top1i Antibody-Drug Conjugate Earned Two Breakthrough Designations
Dr. Dereck Mush, MD, MBA
Solving Healthcare's Hemodynamic Blind Spot: Quantitative Blood Volume Analysis and Inpatient Heart Failure Optimization
Dr. Dereck Mush, MD, MBA
The Post-REMS Long-Acting Psychiatric Revolution: How Subcutaneous Copolymer Delivery Unlocks Olanzapine Outpatient Economics
Dr. Dereck Mush, MD, MBA
Beyond Gluten Avoidance: How argenx's CD122 Blockade Advances Pharmacological Protection in Celiac Disease
Dr. Dereck Mush, MD, MBA
The Skull as Therapeutic Infrastructure: How CraniUS and Chronic Convection Delivery Bypass the Blood-Brain Barrier
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
Synthetic CT and Radiation-Free Orthopedics: The Economics of Single-Modality MRI Surgical Workflows
Dr. Dereck Mush, MD, MBA
The $1.65B Non-Opioid Consolidation: How the NOPAIN Act and Viatris' Buyout Reshape Hospital Analgesic Economics
Dr. Dereck Mush, MD, MBA
Continuous Precision Maintenance: The Economics and Protocols of Chemotherapy-Free HER2 Blockade
Dr. Dereck Mush, MD, MBA
Expanding the Kinase Perimeter: Oral BTK Inhibition in Mechanical and Inducible Autoimmunity
Dr. Dereck Mush, MD, MBA
Reversing the Resistance Cascade: Vascular Reprogramming and Second-Line Antiandrogen Synergy
Dr. Dereck Mush, MD, MBA
Neuroplasticity by Prescription: How Motivista Unlocks Negative Symptoms in Schizophrenia
Dr. Dereck Mush, MD, MBA
Dismantling the 25-Year R-CHOP Monopoly: Frontline Bispecifics and the Future of Lymphoma
Dr. Dereck Mush, MD, MBA
Bridging the Last Mile of Acute Cardiology: Synthesized 3D Vectorcardiography at Home
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
Inverting the GLP-1 Axis: Antagonism and the Unintended Metabolic Casualties of Bariatric Surgery
Dr. Dereck Mush, MD, MBA
From Remote Telemetry to Active Co-Management: Direct-to-Patient Hemodynamics in Heart Failure
Dr. Dereck Mush, MD, MBA
From Algae to Neural Circuits: What the 2026 Medicine Nobel Means for Optogenetics
Dr. Dereck Mush, MD, MBA
Growth-Accommodating Medtech: How Expandable Scaffolds Disrupt Congenital Surgical Cycles
Dr. Dereck Mush, MD, MBA
The Non-Covalent Oncology Paradigm: Jaypirca's Frontline Infiltration and the BTK Landscape
Dr. Dereck Mush, MD, MBA
Opportunistic Valvular Screening: How Routine ECG-AI Expands the Structural Heart Pipeline
Dr. Dereck Mush, MD, MBA
Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
The End of Phase-Gated Trials: How ARPA-H's SURPASS Program Reengineers Biomedical R&D
Dr. Dereck Mush, MD, MBA
From IT Expense to Revenue Driver: How CMS NTAP Activates the Clinical AI Commercial Flywheel
Dr. Dereck Mush, MD, MBA
Decentralizing the Neuro-ICU: The Clinical Economics of Quantitative Bedside Brain Monitoring
Dr. Dereck Mush, MD, MBA
Mobile Optical Diagnostics: Ending the Multibillion-Dollar Emergency Vertigo Workup
Dr. Dereck Mush, MD, MBA
Cyclical Mechanics vs. Static Vacuum: The Next Battleground in Endovascular Thrombectomy
Dr. Dereck Mush, MD, MBA
Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBA
Decentralizing Syndromic PCR: The Point-of-Care Molecular Margin War
Dr. Dereck Mush, MD, MBA
Computer Vision in GI: Transforming Capsule Endoscopy into Asynchronous Care
Dr. Dereck Mush, MD, MBA
The MCT8 Treatment Boundary: What Emcitate's Approval Changes and What It Leaves Open
Dr. Dereck Mush, MD, MBA
The ECG-to-Echo Pathway: Where Tempus ECG-MR Must Prove Its Value
Dr. Dereck Mush, MD, MBA
The Two-Marker CAR-T Test: LNK001's First Patients and the Safety Hypothesis
Dr. Dereck Mush, MD, MBA
The Stentless Cath Lab: What SELUTION SLR Changes for Coronary Intervention
Dr. Dereck Mush, MD, MBA
The D1/D5 Bet: What AbbVie's Juvmo Adds to Parkinson's Care
Dr. Dereck Mush, MD, MBA
The ALK2 Opening: What Atebrioz Means for Rare Bone Disease
Dr. Dereck Mush, MD, MBA
The Once-Weekly Basal Insulin Shift: Inside Lilly's Onswik Approval and the Battle for Metabolic Adherence
Dr. Dereck Mush, MD, MBA
The Biophysical Tumor Barrier: Inside TriSalus's TriNav Advance Clearance and the Fluid Mechanics of Interventional Oncology
Dr. Dereck Mush, MD, MBA
The Coronary Plaque Reimbursement Playbook: Inside Elucid's $55M Raise and the Economics of Non-Invasive Cardiovascular AI
Dr. Dereck Mush, MD, MBA
Upfront Disease Modification: How Winrevair's HYPERION Label Update Rewrites Pulmonary Vascular Care
Dr. Dereck Mush, MD, MBA
The $340M Ambient AI Infrastructure Shift: Why Heidi Is Moving Beyond the Point-Solution Scribe
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
The ANDA Blueprint: How Bravnetsa Reshapes Radiopharmaceutical Competition
Dr. Dereck Mush, MD, MBA
The Algorithmic Panopticon: Why Hospital AI Stalls at the Bedside
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA
Standardizing the Amyloid Frontier: Inside FDA Clearance of MICSI-PET
Dr. Dereck Mush, MD, MBA
The AAV9 CNS Blueprint: Inside Ultragenyx's Landmark Fayuvi Approval
Dr. Dereck Mush, MD, MBA
De Novo AI in the Acute Care Pathway: How Queen of Hearts Redefines Emergency Triage Economics and Cath Lab Utilization
Dr. Dereck Mush, MD, MBA
The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostic Moats, and the Oral SERD Market Shift
Dr. Dereck Mush, MD, MBA
Unlocking Orphan Neuromuscular Indications: Why IntraBio's Aqneursa Approval Signals a Regulatory Re-evaluation of Small-Cohort Crossover Trials
Dr. Dereck Mush, MD, MBA
The EHR Dark Data Goldmine: Why Sentence-Level Provenance Is Pharma's New Real-World Evidence Moat
Dr. Dereck Mush, MD, MBA
The $2.4B Oral Macrocycle and Bispecific Surge: Why Big Pharma Is Buying Platform Engines Over Single Assets
Dr. Dereck Mush, MD, MBA
The Level-Funded Disruption: How Angle Health's $2.7B Valuation Exposes Legacy Payer Fragility in Small-Group Underwriting
Dr. Dereck Mush, MD, MBA
The 33-Year Nephrology Reversal: Inside Kerendia's Type 1 Diabetes Expansion
Dr. Dereck Mush, MD, MBA
Beyond RECIST 1.1: The AI Endpoint Playbook for Modern Oncology Trials
Dr. Dereck Mush, MD, MBA
The Oral Endocrine Pivot: Inside Sling Therapeutics' $123M Bet on Linsitinib
Dr. Dereck Mush, MD, MBA
The Agentic Clinical AI Regulatory Frontier: What ADVOCATE's $62.7M Contract Actually Unlocks
Dr. Dereck Mush, MD, MBA
The AI ECG Cardiology Market After Queen of Hearts: Who the De Novo Clearance Actually Benefits
Dr. Dereck Mush, MD, MBA
The $1 Billion Equity Infrastructure: What the Gates Foundation's AI Health Commitment Means for Global HealthTech Markets
Dr. Dereck Mush, MD, MBA
The Prescribing Agent Playbook: Inside ARPA-H's $62.7M Cardiovascular AI Mandate
Dr. Dereck Mush, MD, MBA
Breaking the PMA Bottleneck: How FDA's Class II Reclassification Accelerates Precision Oncology
Dr. Dereck Mush, MD, MBA
Reclaiming Early Clinical Development: Inside the FDA's Expedited IND Pilot
Dr. Dereck Mush, MD, MBA
The AI-Native Practice Playbook: Why Epsilon Health Built a Medical Group Instead of Selling Software
Dr. Dereck Mush, MD, MBA
Beyond PD-L1: How the I3LUNG Consortium Validated Multimodal AI in 2,365 Advanced Lung Cancer Patients
Dr. Dereck Mush, MD, MBA
The Universal Telemetry Layer: Why Implicity's Cross-Vendor Remote Cardiac Platform Raised $40M
Dr. Dereck Mush, MD, MBA
The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBA
Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA
The Digital Health Valuation Reset: How Sword Health's Acquisition of Headspace Redefines Enterprise Whole-Person Care
Dr. Dereck Mush, MD, MBA
The Non-Invasive Neural Race: Why Apple Absorbed Sonera to Bypass the Skin Barrier
Dr. Dereck Mush, MD, MBA
The Physical AI Shift in Post-Acute Care: Inside Inspiren's $500M+ Bet
Dr. Dereck Mush, MD, MBA
The Great Directory Rollup: How H1 Is Building the Single Source of Truth for Provider Networks
Dr. Dereck Mush, MD, MBA
Healthcare AI Has an ROI Problem: Here Is What the Evidence Actually Shows
Dr. Dereck Mush, MD, MBA
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
Dr. Dereck Mush, MD, MBA
The EHR May Be Becoming the Database: Who Owns the Interface Above It?
Dr. Dereck Mush, MD, MBA